Form 10-Q · Quarterly report
Target Corporation 10-Q, filed Aug 28, 2026
- Filed
- CIK
- 0000027419
- Accession no.
- 0000027419-26-000042
Summary
Target Corporation reported second-quarter 2026 net sales of $26.5 billion, up 5.3% from a year earlier, with comparable sales up 3.8%, and GAAP diluted earnings per share of $4.11, up 100.3%, including after-tax benefits from $994 million in tariff refunds; excluding those refunds, operating income grew about 19%. The company said it is pursuing additional tariff refund claims but cannot estimate their ultimate financial effects amid new U.S. tariffs on most major trading partners.
Key points
- Comparable sales rose 3.8%, driven by a 3.6% increase in traffic and a 0.2% increase in average transaction amount.
- Operating income was $2.6 billion, up 94.4%, including $994 million related to tariff refunds; excluding refunds, operating income growth was approximately 19%.
- Non-merchandise sales grew 20.1%, primarily from the Roundel digital advertising business.
- After-tax return on invested capital was 15.4% for the trailing twelve months ended August 1, 2026, compared with 14.3% a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Financial Summary Second quarter 2026 included the following: •Net Sales of $26.5 billion, an increase of 5.3 percent from the comparable prior-year period, driven by: •A comparable sales increase of 3.8 percent, reflecting a 3.6 percent increase in traffic and a 0.2 percent increase in average transaction amount; •The sales contribution from new stores; and •Non-merchandise sales growth of 20.1 percent, primarily driven by growth in our Roundel digital advertising business offering. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.